Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bold Reforms Needed for India’s Vaccine Industry To Boom - McKinsey

This article was originally published in PharmAsia News

Executive Summary

Pushed by an expanded immunization program and a steady flow of new generation vaccines, India’s vaccine industry could grow to $1.65 billion if projected scenarios unfold.

You may also be interested in...



As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot

MUMBAI - India's vaccines specialist Bharat Biotech is reshaping prices of life-saving vaccines with the announcement that it will make available its rotavirus vaccine at $1 per dose for government supplies once it clears Phase III trials. Bharat Biotech expects the product to be market-ready in the next three years

Merck Aims For Deep Dive Into India's Vaccines Market With RotaTeq Launch; May Bring In Many More

MUMBAI - New Jersey-headquartered Merck & Co's Indian affiliate MSD India is fanning out 150 trained medical representatives in 17 cities to promote a basket of three vaccines - a moderately aggressive measure as compared to a few other similar-sized companies having presence in the segment

As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge

MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel